10-Q: THC Therapeutics Reports Q3 2024 Results, Cites Ongoing Development of dHydronator

THC Therapeutics reported its financial results for the quarter ended April 30, 2024, highlighting a net income of $104,622, despite ongoing operating losses and a going concern qualification.

Summary

• THC Therapeutics, Inc. released its financial results for the third quarter of 2024, showing a net income of $104,622, a significant improvement compared to the net income of $94,355 for the same period last year.
• However, the company continues to face operating losses, with a loss from operations of $379,698 for the quarter and $520,067 for the nine-month period.
• The company's total assets stand at $11,813, while total liabilities are $3,431,644, resulting in a stockholders' deficit of $3,519,831.
• The company's primary focus remains on the development of its patented dHydronator, a sanitizing herb dryer, with plans to begin serial manufacturing once sufficient funds are available.
• The company has a going concern qualification due to its accumulated deficit of $38,953,783 and a net loss of $529,838 for the nine months ended April 30, 2024.
• The company had $849 in cash on hand as of April 30, 2024.
• The company has 40,266,149 shares of common stock issued, with 38,866,149 outstanding as of April 30, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a net income for the quarter but significant operating losses, a going concern qualification, and very limited cash. The company's future is highly dependent on its ability to raise capital and successfully commercialize its product, making the overall sentiment negative.

Positives

• The company achieved a net income of $104,622 for the quarter ended April 30, 2024, a slight increase from the same period last year.
• The company has a granted patent for its dHydronator technology, which could provide a competitive advantage.
• The company has made progress in settling a legal dispute with Iliad Research and Trading, L.P.

Negatives

• The company has a significant accumulated deficit of $38,953,783.
• The company has a going concern qualification, indicating substantial doubt about its ability to continue as a going concern.
• The company's operating loss for the three months ended April 30, 2024, was $379,698, a significant increase from the $58,020 loss in the same period of 2023.
• The company has very limited cash on hand, with only $849 as of April 30, 2024.
• The company has not generated any revenue during the reported periods.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate revenues and raise capital.
• The company has not generated sufficient revenues to finance its operations internally.
• The company's ability to raise additional capital through the future issuances of common stock is uncertain.
• The company faces competition from other commercial herb dryers.
• The company's success depends on the successful development and commercialization of its dHydronator product.

Future Outlook

The company plans to use borrowings and security sales to mitigate the effects of cash flow deficits and intends to seek additional financing in a private equity offering to secure funding for operations. The company also plans to source parts for serial manufacturing of the dHydronator and hire sales and marketing staff as funds are available.

Management Comments

• Management believes that the dHydronator will be attractive to the cannabis and home herb and garden product markets.
• Management plans to attend regional cannabis-related trade shows and offer field testing to legal cannabis growers and suppliers.
• Management intends to hire subject matter expert consultants or employees in the legal cannabis and home herb marketplace to manage the development and sales of our products.

Industry Context

The company operates in the wellness industry, specifically targeting the cannabis and home herb and garden markets with its dHydronator product. The market for herb dryers is competitive, with established players already having significant market share. The company's success will depend on its ability to effectively market and distribute its patented technology.

Comparison to Industry Standards

• The company's lack of revenue and significant operating losses are not in line with industry standards for established companies.
• The company's reliance on debt and equity financing is common for early-stage companies, but the going concern qualification raises concerns about its financial stability.
• The company's dHydronator technology, if successfully commercialized, could provide a competitive advantage over traditional drying methods, which can take up to two weeks compared to the dHydronator's 10-14 hours.
• Competitors like Yofumo Technologies already have commercially available herb dryers, indicating a need for THC Therapeutics to differentiate its product and marketing strategy.
• The company's focus on sanitization in addition to drying could be a key differentiator in the market, as many existing products do not offer this feature.

Legal Proceedings

• The company settled a lawsuit with its former CEO, Parker Mitchell, on or about December 12, 2021.
• The company entered into a Settlement Agreement and Mutual Release with Iliad Research and Trading, L.P. on January 31, 2024, to fully settle all disputes related to the case and arbitration.

Related Party Transactions

• The company has related party transactions including advances from related parties and convertible notes payable to related parties.
• The company borrowed $200,000 from Harvey Romanek, the father of the company's CEO, Brandon Romanek, via a convertible promissory note.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern qualification and accumulated deficit.
• Employees' job security is uncertain due to the company's financial instability.
• Customers are not yet impacted as the company has not launched sales of its product.
• Suppliers and creditors face risk due to the company's limited cash and financial challenges.

Next Steps

• The company plans to source parts for serial manufacturing of the dHydronator.
• The company plans to hire sales and marketing staff as funds are available.
• The company intends to seek additional financing in a private equity offering.
• The company plans to attend regional cannabis-related trade shows and offer field testing to legal cannabis growers and suppliers.

Key Dates

Keywords

dHydronator, herb dryer, cannabis, sanitizing, patent, financial results, going concern, operating loss, net income, stock issuance, preferred stock, derivative liability